{"id":396631,"date":"2020-08-05T00:00:00","date_gmt":"2020-08-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0011-2020-biopharma-agitation-in-bipolar-disorder-and-schizophrenia-special-topics-us-2020\/"},"modified":"2026-03-31T10:44:44","modified_gmt":"2026-03-31T10:44:44","slug":"sptocg0011-2020-biopharma-agitation-in-bipolar-disorder-and-schizophrenia-special-topics-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0011-2020-biopharma-agitation-in-bipolar-disorder-and-schizophrenia-special-topics-us-2020\/","title":{"rendered":"Agitation in Bipolar Disorder and Schizophrenia | Special Topics (US) | 2020"},"content":{"rendered":"<p>Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or even aggression and can occur in both treated and untreated patients. Patients experiencing an agitated episode usually present to the emergency department and are then likely treated with both nonpharmacological and pharmacological interventions (e.g., Eli Lilly\u2019s Zyprexa IM, Pfizer\u2019s Geodon, Galen\u2019s Adasuve) to ameliorate this behavior. Emerging therapies will likely need to demonstrate improved efficacy, safety, and convenience\u00a0of administration\u00a0profiles that would influence physicians\u2019 preference for a brand over the generic alternatives currently available to manage this condition.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>How is the treatment of agitation in BPD\u00a0and schizophrenia evolving, according to interviewed and surveyed physicians? What are their perceptions of current therapies to treat this manifestation?<\/li>\n<li>What are\/will be the drivers and constraints for current and emerging therapies\u2019 use in the treatment of agitation in BPD and schizophrenia patients?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in this area?<\/li>\n<li>How do physicians anticipate incorporating newer therapies in this otherwise largely genericized treatment algorithm?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p><em>Special Topics<\/em> uses quantitative primary research to assess evolving trends and market effects in dynamic disease areas. The product examines topics of high interest within an indication, such as delving into reasons driving physicians\u2019 prescribing decisions or assessing physicians\u2019 receptivity to emerging agents to better understand the nuanced dynamics in the indication.<\/p>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong> 5 interviews with thought-leading psychiatrists Survey of 70 U.S. psychiatrists and 30 emergency department physicians.<\/p>\n<p><strong>Key drugs covered:<\/strong> Current drug classes: atypical (e.g., Pfizer\u2019s Geodon, Eli Lilly\u2019s Zyprexa IM) and typical antipsychotics, and benzodiazepines. Emerging therapies: BioXcel\u2019s BXCL501, Avanir\u2019s AVP-786, Axsome\u2019s AXS-05, and Lundbeck \/ Otsuka\u2019s brexpiprazole.<\/p>\n<p><strong>Key insights provided:<\/strong><\/p>\n<ul>\n<li>Physician-reported treatment practices for\u00a0agitation in BPD\u00a0and schizophrenia<\/li>\n<li>Factors influencing treatment decisions<\/li>\n<li>Physician perceptions of unmet needs in the indication<\/li>\n<li>Anticipated use of select emerging therapies to fulfill\u00a0key unmet needs<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-396631","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bipolar-disorder","biopharma-therapy-areas-schizophrenia","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396631\/revisions"}],"predecessor-version":[{"id":396984,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396631\/revisions\/396984"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=396631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}